France
Sartorius Polyplus is a leading upstream solutions provider for advanced biological and cell and gene therapy production from research to commercial scale. An innovator in nucleic acid delivery, the legacy portfolio features process-centric transfection reagents, kits, and support services. Custom plasmid vector design was integrated into the offer in 2022 as a first measure to expanding the products and services portfolio to help customers (or the industry) optimize process economics while meeting strict scientific and regulatory standards.
We wanted to share that we will not be actively posting or engaging on this LinkedIn account. However, you can continue to stay updated and connect with us over https://www.linkedin.com/showcase/106511553.
We appreciate all the conversations and connections we’ve built here and look forward to continuing them on our other page. Thank you for your support, and we hope to see you there!
Sartorius Polyplus was founded in 2001 and is based in France. The last investment was a €2.50M Venture Round - Polyplus investment at 11 January 2011, with investment from Crédit Mutuel Innovation, CIC Finance, Sudinnova.
